Ascendis Pharma A/S ( ASND) - Stock Earnings
ASND Upcoming earnings
Estimated EPS and revenue columns are available to paid members.
| Date | EPS (actual / est.) | Revenue low (est.) | Revenue (actual / est.) | Revenue high (est.) |
|---|---|---|---|---|
| Nov. 12, 2026 BeforeMarket | 1.08 / — | — | 369.7 million / — | — |
ASND Quarterly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2025Q4 | -39.0 million USD | 287.8 million USD |
| 2026Q1 | 733.1 million USD | 287.2 million USD |
| 2026Q2 | 240.1 million USD | 393.6 million USD |
| 2026Q4 Est. | — | — |
| 2027Q1 Est. | — | — |
| 2027Q2 Est. | — | — |
ASND Yearly earnings
Analyst consensus estimates are available to paid members.
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -532.2 million USD | 294.8 million USD |
| 2024 | -393.7 million USD | 378.7 million USD |
| 2025 | -257.1 million USD | 812.0 million USD |
| 2026 Est. | — | — |
ASND
Price: $276.92
Earnings Per Share: 12.96 USD
P/E Ratio: 19.20
Exchange: NMS
Sector: Healthcare
Industry: Biotechnology
Country: Denmark
Volume: 126716
Ebitda: -36.5 millionMarket Capitalization: 17.0 billion